GSK to Acquire IDRx for ~1.15B, Boosting its GI Cancer Portfolio

Shots: GSK to acquire IDRx incl. its lead candidate IDRX-42, for $1B upfront & ~$150M in regulatory milestones (total ~$1.15B). It will also pay success-based milestones & tiered royalties to Merck KGaA for IDRX-42 IDRX-42 (TKI, small molecule) targets key KIT mutations, responsible for proliferation & survival of tumor cells, & is under P-I/Ib…

BySenior EditorJanuary 13, 2025

NEWS

Gilead and LEO Pharma Join Forces to Develop STAT6 Program for Multiple Inflammatory Disorders

Shots: Gilead has entered into a strategic collaboration with LEO Pharma to develop the latter’s small molecule oral STAT6 programs targeting various inflammatory disorders As per the terms, Gilead secures worldwide rights to develop, manufacture & commercialize LEO’s preclinical STAT6 inhibitors & degrading proteins, with LEO having the option to co-commercialize them for dermatology…

BySenior EditorJanuary 13, 2025

NEWS

Telix to Acquire Therapeutic Assets & Biologics Platform from ImaginAb for ~$230M

Shots: Telix to acquire next-gen. therapeutic pipeline, biologics tech platform as well as research facility focused on protein engineering & discovery from ImaginAb via an asset purchase agreement to bolster its capabilities As per the terms, Telix will acquire candidates incl. DLL3 & integrin αvβ6 antagonist, plus a tech platform utilizing small engineered Ab…

BySenior EditorJanuary 13, 2025

NEWS

Merus and Biohaven Join Forces to Advance Three Bispecific ADC Programs

Shots: Biohaven & Merus have entered into a research collaboration & license agreement to co-develop bispecific ADCs using the former’s ADC conjugation & payload platform plus Merus’ Biclonics tech platform As per the terms, Biohaven will develop preclinical ADCs for 3 Merus’ BsAbs (2 developed via Biclonics & 1 in preclinical) & each is…

BySenior EditorJanuary 13, 2025

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (January 06, 2025 – January 10, 2025)

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars, Animal Health & Biotech. Check out our full report below: Oculis Reports Results from P-II (ACUITY) Study of OCS-05 for Treating Acute Optic Neuritis Read More: Oculis PharmaEssentia Reports Topline Data from P-III (SURPASS-ET) Trial of Ropeginterferon Alfa-2b-Njft (P1101) in Essential…

BySenior EditorJanuary 10, 2025

NEWS

Veralox Therapeutics to Acquire Nudge Therapeutics, Expanding its Portfolio

Shots: Veralox has signed an exclusive agreement to acquire Nudge Therapeutics & its preclinical cyclic AMP-GMP (cGAS) inhibitors. The financial terms were undisclosed As per the terms, Veralox will resume the development of acquired candidates & initiate acquisition upon achievement of downstream milestones In addition, Veralox is developing VLX-1005 (12-LOX inhibitor) for thrombosis linked…

BySenior EditorJanuary 10, 2025

NEWS

Boehringer Ingelheim Licenses Synaffix’s Technology to Boost its ADC Portfolio in Oncology

Shots: BI has entered into an agreement with Synaffix (Lonza’s company) to license the latter’s ADC technology, boosting its oncology pipeline via NBE Therapeutics (BI’s subsidiary) As per the terms, BI will access Synaffix’s platform for a specified but undisclosed number of targets, with the first target nominated & others to follow within a…

BySenior EditorJanuary 10, 2025

NEWS

Light Horse Therapeutics Partners with Novartis to Discover Therapies for Cancer Treatment

Shots: Light Horse has entered into a multi-target partnership with Novartis to discover & develop FIC targets for cancer treatment by using its proprietary chemical libraries & precision genetic editing platform that identifies novel functional domains in disease-critical targets As per the agreement, Light Horse is entitled to receive $25M upfront, $1B research, development…

BySenior EditorJanuary 10, 2025

NEWS

Transcarent to Acquire Accolade for ~$621M

Shots: Transcarent to acquire Accolade with a total equity value of ~$621M, with shareholders receiving $7.03/share in cash, making Accolade private. Closing expected in Q2’25 The acquisition will yield a unified platform with Transcarent’s WayFinding (generative AI), pharmacy benefits & overall care experiences (incl. weight health, cancer & surgery care) & Accolade’s data of…

BySenior EditorJanuary 9, 2025

NEWS

MaaT Pharma Reports Topline Data from the Pivotal P-III (ARES) Trial of MaaT013 for Acute Graft-Versus-Host Disease

Shots: The P-III (ARES) trial assesses MaaT013 as a 3L treatment of acute GI-aGvHD in patients (n=66) refractory to steroids & ruxolitinib across the EU Trial achieved its 1EP, depicting 62% GI-ORR at D28 (38% CR & 20% VGPR); 64% ORR in all evaluable organs (36% CR & 18% VGPR); 54% survival at 12mos.…

BySenior EditorJanuary 9, 2025

Senior Editor

GSK to Acquire IDRx for ~1.15B, Boosting its GI Cancer Portfolio

Gilead and LEO Pharma Join Forces to Develop STAT6 Program for Multiple Inflammatory Disorders

Telix to Acquire Therapeutic Assets & Biologics Platform from ImaginAb for ~$230M

Merus and Biohaven Join Forces to Advance Three Bispecific ADC Programs

PharmaShots Weekly Snapshots (January 06, 2025 – January 10, 2025)

Veralox Therapeutics to Acquire Nudge Therapeutics, Expanding its Portfolio

Boehringer Ingelheim Licenses Synaffix’s Technology to Boost its ADC Portfolio in Oncology

Light Horse Therapeutics Partners with Novartis to Discover Therapies for Cancer Treatment

Transcarent to Acquire Accolade for ~$621M

MaaT Pharma Reports Topline Data from the Pivotal P-III (ARES) Trial of MaaT013 for Acute Graft-Versus-Host Disease

Contact US

OUR INFORMATION

FOLLOW US